摘要
目的探讨经导管动脉栓塞化疗(TACE)联合阿帕替尼治疗老年中晚期肝癌患者的疗效。方法将70例老年中晚期肝癌患者按治疗方式的不同分为研究组(35例)及对照组(35例)。对照组接受TACE治疗,研究组接受TACE联合阿帕替尼治疗。比较两组患者的疗效、不良反应及血管内皮生长因子(VEGF)、甲胎蛋白(AFP)、胱天蛋白酶8(caspase 8)水平。结果研究组患者客观缓解率(ORR)、疾病控制率(DCR)均高于对照组,差异均有统计学意义(P<0.05)。治疗后,研究组患者VEGF、AFP和caspase 8水平均低于对照组,差异均有统计学意义(P<0.05)。研究组患者不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论TACE联合阿帕替尼治疗老年中晚期肝癌患者,可有效提高ORR、DCR,下调VEGF、AFP及caspace 8水平,控制不良反应,具有较高临床应用价值。
Objective To investigate the efficacy of transcatheter arterial chemoembolization(TACE)combined apatinib in the treatment of elderly patients with moderate and advanced hepatocellular carcinoma(HCC).Method A total of 70 elderly patients with moderate and advanced HCC were divided into the control group(n=35,treated with TACE)and study group(n=35,treated with TACE+apatinib)according to different treatment methods.The efficacy,adverse reactions,and levels of vascular endothelial growth factor(VEGF),α-fetal protein(AFP)and caspase 8 were compared between the two groups.Result The objective response rate(ORR)and the disease control rate(DCR)in the study group were higher than those in the control group(P<0.05).After treatment,the levels of VEGF,AFP and caspase 8 in the study group were lower than those in the control group(P<0.05).The total incidence of adverse reactions in the study group was lower than that in the control group(P<0.05).Conclusion TACE+apatinib in elderly patients with moderate and advanced HCC can effectively increase the ORR and DCR,down-regulate the levels of VEGF,AFP and caspase 8,and control the adverse reactions,which has higher clinical application value.
作者
熊诗峰
喻国锋
XIONG Shifeng;YU Guofeng(Department of Emergency,Ji’an Central People’s Hospital(Shanghai Dongfang Hospital Ji’an Hospital),Ji’an 343000,Jiangxi,China;Department of Oncology,Ji’an Central People’s Hospital(Shanghai Dongfang Hospital Ji’an Hospital),Ji’an 343000,Jiangxi,China)
出处
《癌症进展》
2023年第24期2732-2734,2741,共4页
Oncology Progress
基金
江西省卫生健康委科技计划项目(202212836)。
关键词
经导管动脉栓塞化疗
阿帕替尼
老年
中晚期肝癌
疗效
transcatheter arterial chemoembolization
apatinib
elderly
moderate and advanced hepatocellular carci�noma
efficacy
